These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16298040)

  • 1. Endocrine disrupting compounds and prostate cancer.
    Hess-Wilson JK; Knudsen KE
    Cancer Lett; 2006 Sep; 241(1):1-12. PubMed ID: 16298040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms.
    Schröder FH
    Eur Urol; 2008 Jun; 53(6):1129-37. PubMed ID: 18262723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The androgen receptor and mechanisms for androgen independence in prostate cancer.
    Javidan J; Deitch AD; Shi XB; de Vere White RW
    Cancer Invest; 2005; 23(6):520-8. PubMed ID: 16203660
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms underlying the development of androgen-independent prostate cancer.
    Pienta KJ; Bradley D
    Clin Cancer Res; 2006 Mar; 12(6):1665-71. PubMed ID: 16551847
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
    Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The mechanism of hormone-independent recurrence of prostate cancer].
    Fukabori Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():45-52. PubMed ID: 11022683
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
    Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
    Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression.
    Shariat SF; Lamb DJ; Iyengar RG; Roehrborn CG; Slawin KM
    Clin Cancer Res; 2008 Jan; 14(2):607-11. PubMed ID: 18223237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular regulation of androgen action in prostate cancer.
    Dehm SM; Tindall DJ
    J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-apoptotic effect of the androgen receptor in human prostate cancer].
    Shen FY; Li BY
    Zhonghua Nan Ke Xue; 2007 Dec; 13(12):1121-4. PubMed ID: 18284065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen signaling and its interactions with other signaling pathways in prostate cancer.
    Kaarbø M; Klokk TI; Saatcioglu F
    Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
    Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
    Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine and behavioral effects of embryonic exposure to endocrine disrupting chemicals in birds.
    Ottinger MA; Lavoie E; Thompson N; Barton A; Whitehouse K; Barton M; Abdelnabi M; Quinn M; Panzica G; Viglietti-Panzica C
    Brain Res Rev; 2008 Mar; 57(2):376-85. PubMed ID: 18006066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue interactions in prostate development: roles of sex steroids.
    Chung LW; Anderson NG; Neubauer BL; Cunha GR; Thompson TC; Rocco AK
    Prog Clin Biol Res; 1981; 75A():177-203. PubMed ID: 7339625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.